Stay updated on Pembrolizumab in Refractory Meningioma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.
Latest updates to the Pembrolizumab in Refractory Meningioma Clinical Trial page
- Check4 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for a pembrolizumab trial for refractory atypical and anaplastic meningioma, including study design, eligibility, outcome measures, and record dates. The record indicates the study was terminated and is no longer recruiting.SummaryDifference45%
- Check12 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.SummaryDifference0.2%
- Check25 days agoChange DetectedThe ClinicalTrials.gov page remains a 403 Forbidden error page. Its footer revision changes from v3.7.1 to v3.7.2.SummaryDifference0.2%
- Check32 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier was updated from v3.7.0 to v3.7.1.SummaryDifference0.2%
- Check46 days agoChange DetectedThe page previously contained a 403 Forbidden message and a navigation link; these deletions indicate the error state content is removed and normal page content is expected to be shown.SummaryDifference0.5%
- Check53 days agoChange DetectedA 403 Forbidden error page is now displayed when loading the study record, replacing the study details with a standard error screen. The navigation to Home remains visible, but substantive content is blocked by the error.SummaryDifference18%
Stay in the know with updates to Pembrolizumab in Refractory Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.